Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > In Vivo CRO Market

In Vivo CRO Market Trends

Report ID: GMI8993
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

In Vivo CRO Market Trends

Increasing demand for personalized medicine is expected to drive the demand for in vivo CRO services.
Personalized medicine requires a deep understanding of the patient's genetic makeup, lifestyle, and environment to develop targeted therapies. In vivo CRO services play a crucial role in this process by providing expertise in preclinical research, including animal studies to evaluate the safety and efficacy of new drugs and treatments.
Additionally, personalized medicine often involves complex research methodologies, including genetically modified animal models and specialized disease models. Moreover, personalized therapies require rigorous testing and validation to meet regulatory standards. In vivo CROs with experience in navigating regulatory pathways and ensuring compliance are essential for advancing personalized medicine therapies.
In 2023, FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Thus, as personalized medicine continues to advance, the need for specialized CRO services that can conduct complex in vivo studies is expected to increase, driving growth in the in vivo CRO industry.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

In vivo CRO market was valued at USD 4.7 billion in 2023 and is set to grow at 7.8% CAGR from 2024 to 2032, driven by the increasing complexity of drug development process.

The bioanalysis & DMPK studies service segment held 40.6% of the market share in 2023 and is set to grow rapidly by 2032, driven by complexity of new drug candidates, including biologics and gene therapies.

North America in vivo CRO market size was USD 2 billion in 2023 and is set to grow at 7.6% CAGR between 2024 – 2032, driven by well-established pharmaceutical and biotechnology industries.

Biocytogen, Charles River Laboratories International Inc. , Crown Bioscience, Evotec SE, GemPharmatech Co. Ltd., IQVIA Inc., Icon Plc, Labcorp Drug Development, Parexel International Corporation among others.